Clinical Trial Information Request for Protocol 24-251 Title TRADE-DXd: A phase II non-comparative trial of datopotamab deruxtecan (Dato-DXd) or trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-negative (HER2-low or HER2-0) breast cancer after progression on prior antibody drug conjugate therapy PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone